Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864)
AURORA, ON, Jan. 30 /PRNewswire-FirstCall/ - Helix BioPharma Corp. announces that at the Company's Annual General Meeting held on January 29th, 2008, shareholders adopted all of the resolutions presented by management, appointing KPMG LLP as auditor, electing Don Segal, John Docherty, Ken Cawkell, Jack Kay, Slawomir Majewski, and Gordon Lickrish as directors, and approving certain amendments to the Company's by-laws.
Joining the Helix BioPharma board is Professor Slawomir Majewski, Head of the Department of Dermatology and Venereology at the Warsaw School of Medicine in Poland. Professor Majewski's extensive experience in the field of dermatology, and especially sexually transmitted diseases and skin cancer, will be of great benefit to the Board of Directors and the senior management team at Helix.
Retiring from Helix's board are Conor Gunne and Dr. Richard Rossman, who served as directors of Helix for a number of years. "I would like to personally thank both Conor and Richard for their valuable contribution to the Company over the many years and wish them both well in their other endeavors," said Don Segal, CEO of Helix BioPharma.
Helix's management would also like to thank its shareholders for their continued support, and looks forward to the further development of the Company's new drug products, Topical Interferon Alpha-2b and L-DOS47, in the year ahead.
A Report of Voting Results in respect of the Meeting will be posted on the SEDAR website at (http://www.sedar.com).
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.
The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains forward-looking statements regarding the development of the Company's drug products, which statements can be identified by the words "looks forward, "development" and "developing". Actual results or events could differ materially from these forward-looking statements and information due to numerous factors, including without limitation, research & development risks, intellectual property risks; product liability risks; the risk of unanticipated expenses, the need for regulatory approvals which is not assured; the need for clinical trials and uncertainty whether they will occur or will be successful; and possible changes in business strategy or plans. These and other risks and uncertainties are contained in Helix's latest Annual Information Form at http://www.sedar.com. Forward-looking statements and information are based on the assumptions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation, except as required by law, to update any forward-looking statement or information should those assumptions or expectations, or other circumstances change.
|SOURCE Helix BioPharma Corp.|
Copyright©2008 PR Newswire.
All rights reserved